Heron Therapeutics (NASDAQ:HRTX) Now Covered by Analysts at HC Wainwright

Equities researchers at HC Wainwright began coverage on shares of Heron Therapeutics (NASDAQ:HRTX - Get Free Report) in a report issued on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $6.00 price target on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 185.71% from the stock's current price.

Several other research analysts also recently commented on HRTX. Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday. Needham & Company LLC restated a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Stock Performance

HRTX opened at $2.10 on Monday. The firm has a market cap of $320.38 million, a P/E ratio of -11.67 and a beta of 1.15. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The business has a 50 day moving average price of $2.02 and a 200 day moving average price of $1.87.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million. As a group, analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nicolet Advisory Services LLC bought a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $25,000. RFP Financial Group LLC acquired a new stake in Heron Therapeutics in the 1st quarter valued at $26,000. Argent Advisors Inc. acquired a new stake in Heron Therapeutics in the 4th quarter valued at $31,000. Focus Partners Wealth bought a new stake in Heron Therapeutics during the 4th quarter worth about $31,000. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock worth $40,000 after buying an additional 4,619 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.